ATE287673T1 - Kontrolliertes zuführsystem mit einer flüssigkeit von hoher viskosität - Google Patents

Kontrolliertes zuführsystem mit einer flüssigkeit von hoher viskosität

Info

Publication number
ATE287673T1
ATE287673T1 AT96921521T AT96921521T ATE287673T1 AT E287673 T1 ATE287673 T1 AT E287673T1 AT 96921521 T AT96921521 T AT 96921521T AT 96921521 T AT96921521 T AT 96921521T AT E287673 T1 ATE287673 T1 AT E287673T1
Authority
AT
Austria
Prior art keywords
high viscosity
feed system
viscosity liquid
controlled feed
hvlcm
Prior art date
Application number
AT96921521T
Other languages
English (en)
Inventor
Arthur J Tipton
Richard J Holl
Original Assignee
Southern Biosystems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27044421&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE287673(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/474,337 external-priority patent/US5747058A/en
Application filed by Southern Biosystems Inc filed Critical Southern Biosystems Inc
Application granted granted Critical
Publication of ATE287673T1 publication Critical patent/ATE287673T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/20—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing organic materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/44—Medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/001—Use of materials characterised by their function or physical properties
    • A61L24/0015—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0066—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/23—Carbohydrates
    • A61L2300/236—Glycosaminoglycans, e.g. heparin, hyaluronic acid, chondroitin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/42—Anti-thrombotic agents, anticoagulants, anti-platelet agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/602—Type of release, e.g. controlled, sustained, slow
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/62—Encapsulated active agents, e.g. emulsified droplets
    • A61L2300/622—Microcapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/80—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special chemical form
    • A61L2300/802—Additives, excipients, e.g. cyclodextrins, fatty acids, surfactants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Materials Engineering (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Surgery (AREA)
  • Diabetes (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Birds (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT96921521T 1995-06-07 1996-06-07 Kontrolliertes zuführsystem mit einer flüssigkeit von hoher viskosität ATE287673T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47845095A 1995-06-07 1995-06-07
US08/474,337 US5747058A (en) 1995-06-07 1995-06-07 High viscosity liquid controlled delivery system
PCT/US1996/010055 WO1996039995A1 (en) 1995-06-07 1996-06-07 High viscosity liquid controlled delivery system

Publications (1)

Publication Number Publication Date
ATE287673T1 true ATE287673T1 (de) 2005-02-15

Family

ID=27044421

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96921521T ATE287673T1 (de) 1995-06-07 1996-06-07 Kontrolliertes zuführsystem mit einer flüssigkeit von hoher viskosität

Country Status (12)

Country Link
EP (2) EP1525858A1 (de)
JP (3) JP4330175B2 (de)
CN (1) CN1225230C (de)
AT (1) ATE287673T1 (de)
AU (1) AU698281B2 (de)
BR (1) BRPI9609033B8 (de)
CA (1) CA2222567C (de)
DE (1) DE69634277T2 (de)
DK (1) DK1006935T3 (de)
ES (1) ES2238693T3 (de)
PT (1) PT1006935E (de)
WO (1) WO1996039995A1 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413536B1 (en) 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
US5968542A (en) * 1995-06-07 1999-10-19 Southern Biosystems, Inc. High viscosity liquid controlled delivery system as a device
EP1525858A1 (de) * 1995-06-07 2005-04-27 Durect Corporation Kontrolliertes Zuführsystem mit einer Flüssigkeit von hoher Viskosität
US7833543B2 (en) 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
US6051558A (en) * 1997-05-28 2000-04-18 Southern Biosystems, Inc. Compositions suitable for controlled release of the hormone GnRH and its analogs
ATE355821T1 (de) * 1997-06-05 2007-03-15 Roland Bodmeier Multiphasensystem
ES2221127T5 (es) † 1997-12-02 2009-11-10 Pfizer Products Inc. Uso de acitromicina en el tratamiento topico de infecciones oculares.
US6245345B1 (en) * 1998-07-07 2001-06-12 Atrix Laboratories, Inc. Filamentous porous films and methods for producing the same
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
US7056893B2 (en) 1999-03-31 2006-06-06 Insite Vision, Inc. Topical treatment for prevention of ocular infections
JP4601100B2 (ja) * 1999-11-08 2010-12-22 三生医薬株式会社 マスティックの油液を内包した軟カプセル
PT1397155E (pt) 2001-06-21 2015-12-07 Genentech Inc Formulação de libertação sustentada
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
EP2218448B1 (de) 2002-12-13 2015-09-23 Durect Corporation Orale Darreichungsform mit flüssigen hochviskose Trägersystemen
KR20050088196A (ko) * 2002-12-19 2005-09-02 알자 코포레이션 안정한 비수성 단일 상 겔 및 이식가능한 장치로부터전달하기 위한 이의 제형
AU2004279320A1 (en) 2003-09-23 2005-04-21 Ortho Therapeutics, Llc. Bioabsorbable putty-like hemostatic implants
CN102579162A (zh) * 2003-09-23 2012-07-18 奥索康公司 可吸收的植入体和它们用于止血和治疗骨缺损的方法
US8603528B2 (en) 2004-09-16 2013-12-10 Abyrx, Inc. Compositions and method for the reduction of post-operative pain
DK2767292T3 (en) 2004-09-17 2016-12-19 Durect Corp RENEWABLE local anesthetic COMPOSITION CONTAINING SAIB
DE102005002703C5 (de) 2005-01-19 2013-07-04 Heraeus Kulzer Gmbh Antibiotische Beschichtung von Implantaten sowie Verfahren zur antibiotischen Beschichtung
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
US8871183B2 (en) 2006-05-15 2014-10-28 Zicare, Llc Composition for promoting and maintaining oral health
US20070292362A1 (en) * 2006-05-15 2007-12-20 Tim Clarot Method for orthodontia care
AU2007325918B2 (en) 2006-11-03 2013-10-17 Durect Corporation Transdermal delivery systems comprising bupivacaine
EP2152315B1 (de) 2007-05-25 2016-01-06 Indivior UK Limited Formulierungen von risperidon-verbindungen mit verzögerter freisetzung
EP2011452B1 (de) * 2007-07-06 2014-04-30 S.B.I.R. Sprl Injizierbare Zubereitung zum Erhalten eines Muskelimplantat
EP2067471B1 (de) * 2007-12-06 2018-02-14 Durect Corporation Orale arzneimitteldosierformen
WO2009100222A1 (en) * 2008-02-08 2009-08-13 Qps Llc Non-polymeric compositions for controlled drug delivery
EP2254559B1 (de) * 2008-02-08 2018-10-10 Foresee Pharmaceuticals Co., Ltd. Zusammensetzung zur verzögerten freisetzung von proteinen oder peptiden
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
CN103830767A (zh) * 2012-11-26 2014-06-04 韩冰 乙酸异丁酸蔗糖酯凝胶及其用途
CA2905131A1 (en) 2013-03-15 2014-09-18 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
CA2913100C (en) 2013-05-24 2021-10-26 Danmarks Tekniske Universitet Gel formulations for guiding radiotherapy
BR112016012063B1 (pt) * 2013-12-31 2021-02-23 Pb&B Sa composição e usos da mesma
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
US11065201B2 (en) 2014-11-21 2021-07-20 Technical University Of Denmark Gel formulations for local drug release
AU2017266410B2 (en) 2016-05-20 2022-07-14 Nanovi Radiotherapy Aps Palpable marker composition
CN109310680B (zh) * 2016-06-30 2022-11-01 度瑞公司 长效配制物
CN109475505A (zh) 2016-07-06 2019-03-15 度瑞公司 具有药物组成物、屏障层及药物层的口服剂型
EA201990127A1 (ru) * 2016-12-30 2020-08-18 Дьюрект Корпорейшн Депо-препарат
WO2018225050A1 (en) 2017-06-09 2018-12-13 Association For The Advancement Of Tissue Engineering Cell Based Technologies & Therapies (A4Tec) - Associação Sucrose acetate isobutyrate-based compositions, methods and uses thereof
CA3141337A1 (en) * 2019-05-24 2020-12-03 Piedmont Animal Health Inc. Long-acting injectable formulations and use thereof
WO2021146215A1 (en) 2020-01-13 2021-07-22 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods
CA3203561A1 (en) 2021-01-12 2022-07-21 Adrian Neil Verity Sustained release drug delivery systems and related methods
KR102388506B1 (ko) * 2021-06-14 2022-04-20 (주)씨앤엘디 유착방지용 조성물
JP7685185B2 (ja) * 2021-10-13 2025-05-29 株式会社エナジーフロント 抗ウイルス剤、抗ウイルス性を付与する方法、抗ウイルス性を有する物品の製造方法、抗菌剤、抗菌性を付与する方法、抗菌性を有する物品の製造方法、抗真菌剤、抗真菌性を付与する方法、及び抗真菌性を有する物品の製造方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59210024A (ja) * 1983-05-13 1984-11-28 Taiyo Kagaku Kk トコフエロ−ル乳化物
JPS62419A (ja) * 1985-06-26 1987-01-06 Shiseido Co Ltd 脂溶性ビタミン含有水溶性剤
US4938763B1 (en) * 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US4987893A (en) * 1988-10-12 1991-01-29 Rochal Industries, Inc. Conformable bandage and coating material
IL102857A (en) * 1991-08-26 1997-02-18 Abbott Lab Compositions for the sublingual or buccal administration of therapeutic agents which are degraded upon oral administration
IL103275A0 (en) * 1991-10-01 1993-02-21 Lilly Co Eli Injectable extended release formulations and methods
WO1993011754A1 (en) * 1991-12-11 1993-06-24 The Procter & Gamble Company Cetylpyridinium chloride and domiphen bromide in organic solvent
US5340572A (en) * 1993-02-08 1994-08-23 Insite Vision Incorporated Alkaline ophthalmic suspensions
US5370864A (en) * 1993-06-29 1994-12-06 The Procter & Gamble Company Breath protection microcapsules
JPH0753356A (ja) * 1993-08-16 1995-02-28 Morishita Jintan Kk 酸化され易い油性物質を内容物とするシームレスカプセルおよびその製造方法
TW282403B (de) * 1993-08-26 1996-08-01 Takeda Pharm Industry Co Ltd
DE69431071T2 (de) * 1993-12-29 2003-03-20 Matrix Pharma Zusammensetzung für lokale freigabe von zytostatika
EP1525858A1 (de) * 1995-06-07 2005-04-27 Durect Corporation Kontrolliertes Zuführsystem mit einer Flüssigkeit von hoher Viskosität

Also Published As

Publication number Publication date
HK1015255A1 (en) 1999-10-15
JP2009197018A (ja) 2009-09-03
CA2222567C (en) 2002-01-29
AU6273196A (en) 1996-12-30
EP1525858A1 (de) 2005-04-27
CN1225230C (zh) 2005-11-02
BRPI9609033B8 (pt) 2017-04-04
JP2007126459A (ja) 2007-05-24
BR9609033B1 (pt) 2009-08-11
AU698281B2 (en) 1998-10-29
EP1006935B1 (de) 2005-01-26
BR9609033A (pt) 1999-12-14
WO1996039995A1 (en) 1996-12-19
MX9709606A (es) 1998-06-30
CN1192131A (zh) 1998-09-02
DK1006935T3 (da) 2005-06-06
ES2238693T3 (es) 2005-09-01
JP4330175B2 (ja) 2009-09-16
JPH11507278A (ja) 1999-06-29
CA2222567A1 (en) 1996-12-19
DE69634277D1 (de) 2005-03-03
PT1006935E (pt) 2005-06-30
DE69634277T2 (de) 2006-01-05
EP1006935A4 (de) 2001-05-02
EP1006935A1 (de) 2000-06-14

Similar Documents

Publication Publication Date Title
DE69634277D1 (de) Kontrolliertes zuführsystem mit einer flüssigkeit von hoher viskosität
WO1999013913A3 (en) High viscosity liquid controlled delivery system as a device
BR9809189A (pt) Compostos adequados para liberação controlada do hormÈnio gnrh e seus análogos
NZ311208A (en) Composition comprising an active agent dissolved in a glass-forming carrier comprising a glass-forming substance containing a plasticizer, composition is liquid or jelly-like below 50 degrees
ATE200184T1 (de) Arzneimittelhaltiges tierfutter
AU4879396A (en) Use of inorganic aerogels in pharmacy
ES2033820T3 (es) Aparato distribuidor de soluciones de productos quimicos y metodo de utilizarlo.
ES8206183A1 (es) Un procedimiento para la preparacion de un adhesivo analgesico antiflogistico.
YU48299B (sh) Postupak za proizvodnju ransdermalnog terapeutskog sistema za dovođenje aktivnih materija na kožu
DE69407404D1 (de) Feste zubereitung mit hoher freisetzung, ihre herstellung und verwendung
EA199800849A2 (ru) Клеящая композиция для снабжения покрытием изделий плоской формы с применением тепла и давления (ее варианты)
NO307657B1 (no) Forestret stivelsessammensetning, artikkel av samme, fremgangsmÕte for fremstilling av nevnte artikkel samt en smelte
CA2215377A1 (en) Controlled delivery compositions and processes for treating organisms in the environment
FR2772773B1 (fr) Melange stabilisant pour matieres organiques, composition le contenant et son procede d'utilisation
AU2097892A (en) Transdermal estradiol delivery system
IL105646A0 (en) Sulfonylbenzyl-substituted benzo-and pyridopyridones,their preparation and pharmaceutical compositions containing them
DE59803303D1 (de) Niedrigkonzentrierte höherviskose flüssigwaschmittel
AU753954C (en) Process for the at least partial, direct coating of an extensible backing material with a pressure-sensitive adhesive composition
DE3867541D1 (de) Optisch aktives polymer und zusammensetzung von fluessigem kristall, die dieses enthaelt.
EP0651634A1 (de) Vernetztes polyhydroxyl-material zur enzymatisch gesteuerten arzneistofffreisetzung.
MY106039A (en) Anti-dazzling and electrostatic charge-preventive transparent coating material,method thereof and video display coated therewith.
ATE55104T1 (de) Herstellung von ''gossyplure''und 1-metallo-5,9- tetradecadien.
DE59402300D1 (de) Katalysatoren mit hochdisperser verteilung der aktivkomponente
DE3787386D1 (de) In der Behandlung von Östrogeninsuffizienz zu verwendende Zusammensetzung.
JPS57209217A (en) Medicament preparation

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1006935

Country of ref document: EP